Drug Profile


Alternative Names: Aflibercept/Ang2-antibody; Ang2 antibody/Eylea; Ang2-antibody/aflibercept; Eylea/Ang2-antibody; Eylea/nesvacumab; Nesvacumab/aflibercept; Nesvacumab/Eylea; REGN 910-3; REGN-910/Eylea

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 03 Oct 2017 Regeneron Pharmaceuticals completes the phase II ONYX trial in Wet age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT02713204)
  • 10 Jul 2017 Regeneron completes the phase II RUBY trial in Diabetic macular oedema in USA (Intravitreous) (NCT02712008)
  • 10 Feb 2017 Regeneron completes enrolment in the ONYX trial in Wet-age related macular degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top